A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors.

Candelaria, M

A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors. [electronic resource] - Annals of oncology : official journal of the European Society for Medical Oncology Sep 2007 - 1529-38 p. digital

Publication Type: Clinical Trial, Phase II; Journal Article

0923-7534

10.1093/annonc/mdm204 doi


Adolescent
Antineoplastic Combined Chemotherapy Protocols--therapeutic use
DNA Methylation
Drug Resistance, Neoplasm
Epigenesis, Genetic
Female
Histone Deacetylases--metabolism
Humans
Hydralazine--administration & dosage
Male
Neoplasms--drug therapy
Valproic Acid--administration & dosage